"Many alternative terms have been used over the years including cavernous haemangioma, cerebral cavernous malformation or simply cavernoma. As these lesions are not neoplastic, it has been argued that the terms 'haemangioma' and 'cavernoma' should be avoided. Additionally, it is important to note that according to newer nomenclature (ISSVA classification of vascular anomalies) these lesions are now officially termed slow flow venous malformations."
"Many alternative terms have been used over the years including cavernous haemangioma, cerebral cavernous malformation or simply cavernoma. As these lesions are not neoplastic, it has been argued that the terms 'haemangioma' and 'cavernoma' should be avoided. Additionally, it is important to note that according to newer nomenclature (ISSVA classification of vascular anomalies) these lesions are now officially termed slow flow venous malformations."
"Many alternative terms have been used over the years including cavernous haemangioma, cerebral cavernous malformation or simply cavernoma. As these lesions are not neoplastic, it has been argued that the terms 'haemangioma' and 'cavernoma' should be avoided. Additionally, it is important to note that according to newer nomenclature (ISSVA classification of vascular anomalies) these lesions are now officially termed slow flow venous malformations."
"For clarity and brevity, the term cerebral cavernous malformation is used for the remainder of this article, inclusive of infratentorial cavernous malformations as well (which are not technically 'cerebral')."
Expected headings
"Associations"
"Classification"
"Cerebral cavernous malformations have an incidence of 0.15-0.56 per 100,000 persons, and autopsy prevalence of ~0.5% 17,18. The symptomatic prevalence, however, is much lower, estimated at 0.04% 17. Most patients who present symptomatically do so at 20-40 years of age, however, any age group, including paediatrics, can be affected 17,18. Around 40% (range 20-50%) of cavernous malformations are incidental findings on neuro-imaging 13,14. There is no difference among men and women 17."
"T1 C+ (Gd): cavernous malformations may show enhancement; post-contrast sequences useful to detecting associated DVAs 7,18"
"haemorrhagic metastases (e.g. melanoma)"
"haemorrhagic primary brain tumours (e.g. ependymoma, glioblastoma)"